Clinical trial
Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in…
NCT00255528 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00255528 |
|---|---|
| Title | Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects |
| Official title | Dose Ranging, Safety and Tolerability of TOPROL-XL® (Metoprolol Succinate) Extended-Release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study |
| Acronym | 307A |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | metoprolol succinate |
| Enrollment | 144 |
| Start date | Jul 1, 2002 |
| First posted | Nov 21, 2005 |
| Last update posted | Mar 20, 2007 |
| Countries | Dominican Republic, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: